These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 27286453)

  • 1. UCN-01 enhances cytotoxicity of irinotecan in colorectal cancer stem-like cells by impairing DNA damage response.
    Signore M; Buccarelli M; Pilozzi E; De Luca G; Cappellari M; Fanciulli M; Goeman F; Melucci E; Biffoni M; Ricci-Vitiani L
    Oncotarget; 2016 Jul; 7(28):44113-44128. PubMed ID: 27286453
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined PDK1 and CHK1 inhibition is required to kill glioblastoma stem-like cells in vitro and in vivo.
    Signore M; Pelacchi F; di Martino S; Runci D; Biffoni M; Giannetti S; Morgante L; De Majo M; Petricoin EF; Stancato L; Larocca LM; De Maria R; Pallini R; Ricci-Vitiani L
    Cell Death Dis; 2014 May; 5(5):e1223. PubMed ID: 24810059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models.
    Ma CX; Cai S; Li S; Ryan CE; Guo Z; Schaiff WT; Lin L; Hoog J; Goiffon RJ; Prat A; Aft RL; Ellis MJ; Piwnica-Worms H
    J Clin Invest; 2012 Apr; 122(4):1541-52. PubMed ID: 22446188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of cytotoxicity of topoisomerase i poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe.
    Tse AN; Schwartz GK
    Cancer Res; 2004 Sep; 64(18):6635-44. PubMed ID: 15374978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 4-Acetylantroquinonol B inhibits colorectal cancer tumorigenesis and suppresses cancer stem-like phenotype.
    Chang TC; Yeh CT; Adebayo BO; Lin YC; Deng L; Rao YK; Huang CC; Lee WH; Wu AT; Hsiao M; Wu CH; Wang LS; Tzeng YM
    Toxicol Appl Pharmacol; 2015 Oct; 288(2):258-68. PubMed ID: 26235807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CHK1-targeted therapy to deplete DNA replication-stressed, p53-deficient, hyperdiploid colorectal cancer stem cells.
    Manic G; Signore M; Sistigu A; Russo G; Corradi F; Siteni S; Musella M; Vitale S; De Angelis ML; Pallocca M; Amoreo CA; Sperati F; Di Franco S; Barresi S; Policicchio E; De Luca G; De Nicola F; Mottolese M; Zeuner A; Fanciulli M; Stassi G; Maugeri-Saccà M; Baiocchi M; Tartaglia M; Vitale I; De Maria R
    Gut; 2018 May; 67(5):903-917. PubMed ID: 28389531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comet assay measures of DNA damage as biomarkers of irinotecan response in colorectal cancer in vitro and in vivo.
    Wood JP; Smith AJ; Bowman KJ; Thomas AL; Jones GD
    Cancer Med; 2015 Sep; 4(9):1309-21. PubMed ID: 26108357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-clinical characterization of PKC412, a multi-kinase inhibitor, against colorectal cancer cells.
    Li JP; Huang ZJ; Lu XS; Zhou YC; Shao Y; He XP; Chen SR; Wang DD; Qin LS; Sun WH
    Oncotarget; 2016 Nov; 7(47):77815-77824. PubMed ID: 27780925
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational development of synergistic combinations of chemotherapy and molecular targeted agents for colorectal cancer treatment.
    Tosi D; Pérez-Gracia E; Atis S; Vié N; Combès E; Gabanou M; Larbouret C; Jarlier M; Mollevi C; Torro A; Del Rio M; Martineau P; Gongora C
    BMC Cancer; 2018 Aug; 18(1):812. PubMed ID: 30103709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCG2 inhibitor YHO-13351 sensitizes cancer stem/initiating-like side population cells to irinotecan.
    Shishido Y; Ueno S; Yamazaki R; Nagaoka M; Matsuzaki T
    Anticancer Res; 2013 Apr; 33(4):1379-86. PubMed ID: 23564776
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
    Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
    Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer.
    Ma CX; Ellis MJ; Petroni GR; Guo Z; Cai SR; Ryan CE; Craig Lockhart A; Naughton MJ; Pluard TJ; Brenin CM; Picus J; Creekmore AN; Mwandoro T; Yarde ER; Reed J; Ebbert M; Bernard PS; Watson M; Doyle LA; Dancey J; Piwnica-Worms H; Fracasso PM
    Breast Cancer Res Treat; 2013 Jan; 137(2):483-92. PubMed ID: 23242585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
    Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
    Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer.
    Ruihua H; Mengyi Z; Chong Z; Meng Q; Xin M; Qiulin T; Feng B; Ming L
    Oncotarget; 2016 Dec; 7(52):87136-87146. PubMed ID: 27888624
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical development of the novel Chk1 inhibitor SCH900776 in combination with DNA-damaging agents and antimetabolites.
    Montano R; Chung I; Garner KM; Parry D; Eastman A
    Mol Cancer Ther; 2012 Feb; 11(2):427-38. PubMed ID: 22203733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ginsenoside Rg3 targets cancer stem cells and tumor angiogenesis to inhibit colorectal cancer progression in vivo.
    Tang YC; Zhang Y; Zhou J; Zhi Q; Wu MY; Gong FR; Shen M; Liu L; Tao M; Shen B; Gu DM; Yu J; Xu MD; Gao Y; Li W
    Int J Oncol; 2018 Jan; 52(1):127-138. PubMed ID: 29115601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models.
    Troiani T; Napolitano S; Martini G; Martinelli E; Cardone C; Normanno N; Vitagliano D; Morgillo F; Fenizia F; Lambiase M; Formisano L; Bianco R; Ciardiello D; Ciardiello F
    Clin Cancer Res; 2015 Sep; 21(18):4153-64. PubMed ID: 26019172
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-expression of Lgr5 and CXCR4 characterizes cancer stem-like cells of colorectal cancer.
    Wu W; Cao J; Ji Z; Wang J; Jiang T; Ding H
    Oncotarget; 2016 Dec; 7(49):81144-81155. PubMed ID: 27835894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regorafenib (BAY 73-4506): antitumor and antimetastatic activities in preclinical models of colorectal cancer.
    Schmieder R; Hoffmann J; Becker M; Bhargava A; Müller T; Kahmann N; Ellinghaus P; Adams R; Rosenthal A; Thierauch KH; Scholz A; Wilhelm SM; Zopf D
    Int J Cancer; 2014 Sep; 135(6):1487-96. PubMed ID: 24347491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice.
    Yao M; Kargman S; Lam EC; Kelly CR; Zheng Y; Luk P; Kwong E; Evans JF; Wolfe MM
    Cancer Res; 2003 Feb; 63(3):586-92. PubMed ID: 12566300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.